• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Insulet Corporation

    5/29/25 4:02:08 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care
    Get the next $PODD alert in real time by email
    SD 1 formsd2025-05x29.htm SD Document

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     

    FORM SD
    SPECIALIZED DISCLOSURE REPORT
     

    INSULET CORPORATION
    (Exact name of registrant as specified in its charter)
     
    Delaware
    (State or other jurisdiction
    of incorporation or organization)
     
    001-33462 04-3523891
    (Commission File Number) (I.R.S. Employer Identification No.)
     
    100 Nagog Park
    Acton, Massachusetts
     01720
    (Address of principal executive offices) (Zip code)
    John W. Kapples
    Senior Vice President and General Counsel
    (978) 600-7000
    (Name and telephone number, including area code, of the person to contact in connection with this report.)
     
     
    Check the appropriate box to indicate the rule pursuant to which this form is being submitted, and provide the period to which the information in this form applies:
     
    ☒Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.
    ☐Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended December 31, 2024.


    Item 1.01Conflict Minerals Disclosure and Report
    This Form SD of Insulet Corporation (the “Company”) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2024 to December 31, 2024.

    A copy of the Company’s Conflict Minerals Report is filed as Exhibit 1.01 to this Form SD and is publicly available at https://investors.insulet.com/ESG.
     
    Item 1.02Exhibit
    A Conflict Minerals Report required by Item 1.01 covering the period January 1, 2024 to December 31, 2024 has been filed as Exhibit 1.01 to this Form SD.
     
    Item 3.01Exhibits
    The following exhibit is filed as part of this Form SD.
    Exhibit No.  Description of Exhibit
    1.01
      2024 Conflict Minerals Report of Insulet Corporation.


    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     
      INSULET CORPORATION
    Date: May 29, 2025  By: /s/ John W. Kapples
       John W. Kapples
       Senior Vice President and General Counsel
    Get the next $PODD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PODD

    DatePrice TargetRatingAnalyst
    6/16/2025$365.00Buy
    Truist
    5/30/2025$380.00Buy
    Goldman
    5/13/2025$350.00Peer Perform → Outperform
    Wolfe Research
    4/29/2025Outperform → Peer Perform
    Wolfe Research
    3/6/2025$340.00Outperform
    RBC Capital Mkts
    11/6/2024$300.00Outperform
    Bernstein
    5/30/2024$235.00Buy
    Redburn Atlantic
    5/7/2024$200.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Insulet with a new price target

      Truist initiated coverage of Insulet with a rating of Buy and set a new price target of $365.00

      6/16/25 7:50:27 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on Insulet with a new price target

      Goldman initiated coverage of Insulet with a rating of Buy and set a new price target of $380.00

      5/30/25 8:41:35 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $350.00

      5/13/25 8:51:02 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Leadership Updates

    Live Leadership Updates

    See more
    • Insulet Appoints Ashley McEvoy President and CEO

      Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig

      4/28/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Host Investor Day on June 5, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company

      3/11/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      8/29/24 4:17:26 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

      4 - INSULET CORP (0001145197) (Issuer)

      9/21/23 4:48:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care